Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.

Additional Information

Product Name: Also Known As: Catalog No.: Size: CAS: Formula: Molecular Weight: Form: Quality Assurance: Source: Storage: PDF Data Sheet: Image(s): Shipping Method: References:

Ixazomib (MLN-2238)

[(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid

F1111

25 mg

1072833-77-2

C14H19BCl2N2O4

361.03 Da

Lyophilized powder

>98% by HPLC and NMR

Synthetic

Eligible for room temperature shipping. Store at -80°C upon receiving

Download PDF datasheet

N/A

Room temperature shipping

N/A

Details

Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.Solubility: > 10 mg/ml in DMSO, 30 mg/mL in 0.5% hydroxyethyl cellulose

>>> 更多资讯详情请访问蚂蚁淘商城